Achievements

Achievements

Publications | Industry Partners

Publications

Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA, the U.S. Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortants vaccines in US children. JAMA 1995;273:1191-1196

Dennehy PH, Rodgers GC, Ward RL, Markwick AJ, Mack M, Zito ET, the U.S. Rhesus Rotavirus Vaccine Study Group. Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. Pediatr Infect Dis J 1996;15:1012-1018

West DJ, Rabalais GP, Watson B, Keyserling HL, Matthews H, Hesley TM. Antibody response of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines. BioDrugs 2001;15:413-418

Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Connor EM,  and Sondheimer HM for the Cardiac Synagis Study Group. Palivizumab Prophylaxis Reduces Hospitalization due to Respiratory Syncytial Virus in Young Children with Hemodynamically Significant Congenital Heart Disease. J Pediatr 2003;143:532-540

Shinefield H, WilliamsWR, Black S, Marchant C, Reisinger K, Stewart T, Meissner HC, GuerreroJ, Klopfer SO, Schödel F, Kuter BJ, The Dose Selection Study Group for ProQuad. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J 2005;24:670-675

Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, Wang E, Mills E. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005;293:3003-3011

Reisinger KS, Hoffman Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Protocol 014 Study Group for ProQuad, Schödel F, Gress JO, Kuter BJ. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-R™II and VARIVAX. Pediatrics 2006;117:265-272

Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L, Schödel F, Hoffman Brown ML, Kuter B, The 013 Study Group for ProQuadâ. Safety and immunogenicity of a measles, mumps, rubella, and varicella vaccine given with combined Haemophilusinfluenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J 2006;25:287-292

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CDC, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM, REST (Protocol 006) Study Team. Safety and efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine in preventing rotavirus gastroenteritis and reducing associated healthcare resource utilization. N Engl J Med 2006;354:23-33 (cited as 2006 Paper of the Year by The Lancet [Butcher J. Lancet 2007;369:91-92])

Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, Boutriau D, HibMenCY-TT 005 Study Group. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010;29:48-52

Marshall GS, Marchant CD, Blatter M, Aris E, Boutriau D, Poolman JT, Friedland LR, Miller JM. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12-15 months of age. Pediatr Infect Dis J 2010;29:469-471

Bryant K, Block S, Baker S, Gruber W, Scott D. Safety and Immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010;125:866-875.

Marshall GS, Marchant CD, Blatter M, Friedland LR, Aris E, Miller JM. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States. Human Vaccines 2011;7:1-7

Bernstein HH, Noriega F, M5A07 Pentacel Study Group. Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: a randomized, open-label, phase 3 study. Vaccine 2011;29:2212-2221

Bryant KA, Marshall GS, Marchant CD, Pavia-Ruz N, Nolan T, Rinderknecht S, Blatter M, Aris E, Lestrate P, Boutriau D, Friedland LR, Miller JM. Immunogenicity and safety of H influenza type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics 2011;127:e1375-e1385

Leonardi M, Bromberg K, Baxter R, Gardner JL, Klopfer S, Nicholson O, Brockley M, Trammel J, Leamy V, Williams W, Kuter B, Schödel F (ProQuad Protocol 019 Study Team). Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children. Pediatrics 2011;128:e1387-e1394

Wheeler CM, HarveyBM, PichicheroME, SimonMW, CombsSP, BlatterMM, MarshallGS, CatteauG, DobbelaereK, DescampsD, DubinG, Schuind A.Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls aged 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J 2011;30:e225-e234

Bryant KA, Marshall GS. A novel combined H. influenzae type b–N. meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Expert Rev Vaccines 2011;10:941-950

BryantKA, McVernonJ, MarchantCD, Nolan T, Marshall GS, RichmondP, Marshall H, Nissen M, Lambert SB, Aris E, Mesaros N, Miller JM. Immunogenicity and safety of measles–mumps–rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y–tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials in toddlers. Hum Vacc Immunother 2012;8:1-6 (http://dx.doi.org/10.4161/hv.20357)

Bryant KA, Gurtman A, Girgenti D, Reisinger K, Johnson A, Pride MW, Patterson S, Devlin C, Gruber WC, Emini EA, Scott DA. Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:383-388

Marshall GS, Blatter M, Aris E, Mesaros N, Miller JM. Antibodies persist for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age Pediatr Infect Dis J 2013;32:662-668

Marshall GS, Pool V, Greenberg DP, Johnson DR, Sheng X, Decker MD. Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of age. Clin Vac Immunol 2014;21:1560-1564


Industry Partners

Abbott Laboratories
Alliance
Bayer
Boehringer Ingelheim
Bristol-Meyers Squibb
Chiltern International, Inc.
Covance
Chiron
Dalichi
GlaxoSmithKline
I-3 Research
ICON
INC Research
Janssen
Johnson & Johnson
Mead Johnson & Co
MedImmune
Merck & Co.
Novartis
Parexel International Corp.
PPD Development
PRA Health
Pfizer, Inc.
Pharmacia & Upjohn
PharmaNet LLC
Quintiles
Reliant
Roche
Ross Products Division
Sanofi-Pasteur
Sclavo
Sepracor
Vyteris
Wyeth
Zeneca